Document is current
Any future updates will be listed below
-
Authors
Tompson, Debra https://orcid.org/0000-0003-1030-2611
Whitaker, Mark https://orcid.org/0000-0003-3062-2129
Pan, Rennan https://orcid.org/0000-0002-2849-3666
Johnson, Geoffrey https://orcid.org/0000-0001-7931-494X
Fuller, Teresa https://orcid.org/0000-0003-4008-0570
Zann, Vanessa https://orcid.org/0000-0003-0747-181X
McKenzie, Litza https://orcid.org/0000-0002-8828-8867
Abbott-Banner, Kathy https://orcid.org/0000-0003-1470-7368
Hawkins, Simon https://orcid.org/0000-0002-2180-5305
Powell, Marcy https://orcid.org/0000-0001-6528-4663
-
Funding
Funding for this research was provided by:
GlaxoSmithKline
- License Information
-
More Information
Article History
Received: 8 March 2021
Accepted: 12 October 2021
First Online: 5 January 2022
Declarations
:
: DT, MW, RP, GJ, TF, KA-B, and MP are employees of and hold equity stock in GlaxoSmithKline (GSK). SH is a former employee of and stockholder in GSK. VZ and LM are employees of Quotient Sciences Limited, where the study was conducted.
: The study was approved by the Wales Research Ethics Committee 2 and was conducted according to the recommendations of Good Clinical Practice and the 1964 Declaration of Helsinki and its later amendments.
: Informed consent was obtained from all individual subjects included in the study.
: The datasets generated during and/or analysed during the current study are not publicly available. Within 6 months of this publication, anonymized individual subject data, the annotated case report form, protocol, reporting and analysis plan, data set specifications, raw dataset, analysis-ready dataset, and clinical study report will be available for research proposals approved by an independent review committee. Proposals should be submitted to . A data access agreement will be required.
